Results from the efficacy portion of the Phase 3 SOLARIS trial
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell, today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749…
